Special Issue

Acute Myeloid Leukemia: Current Progress and Future Directions

Message from the Guest Editors

Acute myeloid leukemia (AML) is an aggressive malignancy spanning heterogenous clinical and molecular phenotypes. In recent years, huge advances in our understanding of the disease's biology have led us to gain deeper insight into the genetic features and the bone marrow microenvironment changes underpinning the process of leukemogenesis, paving the way to targeted treatments. This Special Issue will focus on the recent advances concerning all facets of personalized AML management, including both treatment investigations and translational research, as well as the bench-side management of complications and all-day practice. Moreover, current and future risk disease stratifications, prognostic markers and models, and applications of novel techniques regarding the disease's multimodal nature will be considered. We will highly appreciate and welcome the submissions of original papers and reviews in line with the aim of this Special Issue.

Guest Editors

Dr. Valeria Visconte
Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
Dr. Luca Guarnera
Hematology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy

Deadline for manuscript submissions

15 October 2026

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/si/211642

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

MDPI

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/journal/jpm

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical
subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).

MDPI